Mitochondrial protein interaction landscape of SS-31

Mitochondrial dysfunction underlies the etiology of a broad spectrum of diseases including heart disease, cancer, neurodegenerative diseases, and the general aging process. Therapeutics that restore healthy mitochondrial function hold promise for treatment of these conditions. The synthetic tetrapep...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 117; no. 26; pp. 15363 - 15373
Main Authors Chavez, Juan D., Tang, Xiaoting, Campbell, Matthew D., Reyes, Gustavo, Kramer, Philip A., Stuppard, Rudy, Keller, Andrew, Zhang, Huiliang, Rabinovitch, Peter S., Marcinek, David J., Bruce, James E.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 30.06.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Mitochondrial dysfunction underlies the etiology of a broad spectrum of diseases including heart disease, cancer, neurodegenerative diseases, and the general aging process. Therapeutics that restore healthy mitochondrial function hold promise for treatment of these conditions. The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown. Reportedly, SS-31 primarily interacts with the phospholipid cardiolipin in the inner mitochondrial membrane. Here we utilize chemical cross-linking with mass spectrometry to identify protein interactors of SS-31 in mitochondria. The SS-31-interacting proteins, all known cardiolipin binders, fall into two groups, those involved in ATP production through the oxidative phosphorylation pathway and those involved in 2-oxoglutarate metabolic processes. Residues cross-linked with SS-31 reveal binding regions that in many cases, are proximal to cardiolipin–protein interacting regions. These results offer a glimpse of the protein interaction landscape of SS-31 and provide mechanistic insight relevant to SS-31 mitochondrial therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Edited by Carol Robinson, University of Oxford, Oxford, United Kingdom, and approved May 8, 2020 (received for review February 6, 2020)
Author contributions: J.D.C., P.S.R., D.J.M., and J.E.B. designed research; J.D.C., M.D.C., G.R., P.A.K., R.S., and H.Z. performed research; J.D.C. and A.K. contributed new reagents/analytic tools; J.D.C., X.T., A.K., and J.E.B. analyzed data; and J.D.C., X.T., D.J.M., and J.E.B. wrote the paper.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.2002250117